Investigating the link between immune thrombocytopenia and cancer
Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer
This study looks at whether having immune thrombocytopenia (ITP) is linked to cancer and if cancer cells might cause the body to attack its own platelets.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 70 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Locations | 20 sites (Bondy and 19 other locations) |
| Trial ID | NCT06444477 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the relationship between immune thrombocytopenia (ITP) and various cancers, particularly focusing on the hypothesis that tumor cells may trigger an autoimmune response against platelets. By collecting retrospective data from multiple centers, the study will analyze patient demographics, treatment histories, and outcomes related to both ITP and cancer. The goal is to better understand how chronic expression of certain proteins by tumor cells could lead to the development and persistence of ITP in cancer patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients who have been diagnosed with both immune thrombocytopenia and cancer, with the onset of ITP occurring within six months of the cancer diagnosis.
Not a fit: Patients who do not have a diagnosis of both ITP and cancer will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights that lead to improved management and treatment strategies for patients suffering from ITP associated with cancer.
How similar studies have performed: While the association between ITP and hematologic malignancies is well-documented, the exploration of this link with solid tumors is less established, making this study a novel investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients with a definite diagnosis of both ITP and cancer; * Synchronous diagnosis of ITP and cancer; * Onset of ITP occurring 6 months before or after the diagnosis of cancer. Exclusion Criteria: * None
Where this trial is running
Bondy and 19 other locations
- AP-HP Hôpital Jean Verdier service de médecine interne — Bondy, France (Recruiting)
- CHU de Clermont-Ferrand - service de médecine interne — Clermont-Ferrand, France (Recruiting)
- AP-HP Hôpital Mondor service de médecine interne — Créteil, France (Recruiting)
- AP-HP Hôpital Bicêtre service de médecine interne — Le Kremlin-Bicêtre, France (Recruiting)
- CHU de Lille - service d'Hématologie — Lille, France (Not_yet_recruiting)
- HCL - service d'Hématologie — Lyon, France (Not_yet_recruiting)
- AP-HM Hôpital la Timone - service de médecine interne — Marseille, France (Recruiting)
- CHU de Montpellier - service d'Hématologie — Montpellier, France (Not_yet_recruiting)
- CHRU de Nancy - service de Médecine Interne et Immunologie Clinique — Nancy, France (Recruiting)
- CHU de Nantes - service de médecine interne — Nantes, France (Not_yet_recruiting)
- CHRU d'Orléans - service de Médecine interne — Orléans, France (Not_yet_recruiting)
- CHRU d'Orléans - service de réanimation — Orléans, France (Not_yet_recruiting)
- AP-HP Hôpital Bichat service de médecine interne — Paris, France (Not_yet_recruiting)
- AP-HP Hôpital Saint-Antoine service de médecine interne — Paris, France (Not_yet_recruiting)
- AP-HP Hôpital Saint-Louis service immuno-hématologie — Paris, France (Recruiting)
- CHU de Bordeaux Service de Médecine Interne et Maladies Infectieuses — Pessac, France (Recruiting)
- CHU de Poitiers - service de médecine interne — Poitiers, France (Recruiting)
- CHRU de Strasbourg - service de médecine interne — Strasbourg, France (Not_yet_recruiting)
- CHU de Toulouse - service de médecine interne — Toulouse, France (Not_yet_recruiting)
- CHU de Tours - service de médecine interne — Tours, France (Recruiting)
Study contacts
- Principal investigator: Etienne RIVIERE, MD — University Hospital, Bordeaux
- Study coordinator: Etienne RIVIERE, MD
- Email: etienne.riviere@chu-bordeaux.fr
- Phone: (0)557656483
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.